|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analysis of 4 subgroups (Cognitive impairment ± and Biomarkers ±) showed significant associations of dementia and CSF biomarker concentrations to mortality after an AHF.
|
31508810 |
2020 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A diagnosis of dementia is currently made in terms of probability and is based on clinical evaluation (neuropsycological tests) as well as on the results of morphological imaging investigations (MRI) that can be supported by biohumoral (CSF analysis), and functional imaging only in the case of uncertain diagnosis of disease.
|
31802055 |
2020 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cerebrospinal fluid (CSF) biomarkers are widely used in the diagnosis of dementia.
|
31104469 |
2020 |
|
Dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 1,081 adults without dementia (375 healthy subjects and 706 individuals with mild cognitive impairment) were recruited from the Alzheimer's Disease Neuroimaging Initiative (ADNI) to test the influence of BDNF Val66Met polymorphism on cognitive impairment, brain structure atrophy, and change in the levels of CSF biomarkers.
|
30775992 |
2019 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognostic models were developed by Cox regression with patient characteristics, MRI, and/or CSF biomarkers to predict clinical progression to MCI or dementia.
|
30987684 |
2019 |
|
Dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We included 768 patients (subjective cognitive decline (SCD, n = 194), mild cognitive impairment (MCI, n = 127), dementia (AD and non-AD, n = 447) with amyloid-β PET and CSF Aβ<sub>42</sub> measurement within 1 year.
|
31810489 |
2019 |
|
Dementia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CSF and serum/plasma NfL levels were significantly increased in patients with neurodegenerative dementia diseases.
|
31026486 |
2019 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CSF PlGF is increased in FTD compared with other dementia disorders, MCI, and healthy controls and might be useful as a diagnostic biomarker of FTD.
|
31139684 |
2019 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Baseline CSF biomarkers (amyloid beta (Aβ) 1-42, Aβ42/40, Tau, and pTau181), interpreted according to the ES, were used to estimate time to progression from the MCI stage of AD to ADD, conditional on age, gender, APOE ε4 genotype, and Mini Mental State Examination score in 144 MCI subjects, using the Extended Cox Model; the subjects were followed-up until they developed dementia or until they had been cognitively stable for at least 2 years.
|
30611311 |
2019 |
|
Dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Subjects with dementia and Mild Cognitive Impairment (MCI) due to AD have been found to have higher CSF cortisol levels than cognitively healthy controls.
|
30881301 |
2019 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, looking into the multifactorial nature of AD and the overlapping pathology with other forms of dementia, it is important to integrate the core CSF biomarkers with a broader panel of other biomarkers reflecting different aspects of pathology.
|
30770953 |
2019 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated the prognostic utility of identifying longitudinal neuropsychological decline along with single cognitive exam and Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers in predicting dementia.
|
31104015 |
2019 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We measured CSF AD biomarkers' concentrations in a sample of 526 patients with a clinical diagnosis of dementia (277 with AD and 249 with Other Type of Dementia, OTD).
|
31345148 |
2019 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several CSF biomarkers have been evaluated for their utility in diagnostic processes in different neurodegenerative dementias; however, evidence regarding their role in neurodegenerative overlaps is still limited.
|
31400306 |
2019 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The finding that amnestic MCI based on brief neuropsychological assessment is significantly associated with CSF biomarkers for cognitive decline and Alzheimer's disease is in accordance with longitudinal studies that find memory impairment; both in itself and especially in combination with other cognitive deficit to constitute a risk factor for subsequent cognitive decline and dementia.
|
30614807 |
2019 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nevertheless, the association between cSS and core cerebrospinal fluid (CSF) biomarkers for dementia remain unclear.
|
31105644 |
2019 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays.
|
31836810 |
2019 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This may indicate that Aβ levels in the CSF are affected significantly by ventriculomegaly and not as much by pathophysiological pathways characteristic for each dementia entity.
|
29324921 |
2019 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Potential predictors included CSF biomarkers, cognitive performance (verbal learning and memory), apolipoprotein E (APOE) ε4 genotype, medial temporal lobe atrophy, family history of dementia, depressive symptoms, and vascular factors, including the Cardiovascular Risk Factors, Aging and Dementia (CAIDE) risk score.
|
31805990 |
2019 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thereafter, we focused on the four miRNAs that showed group differences and measured their content in neurally derived blood EVs isolated from 63 subjects: 16 patients with early stage dementia and a CSF Aβ42+ tau profile consistent with AD, 16 individuals with mild cognitive impairment (MCI) and an AD CSF profile, and 31 cognitively intact controls with normal CSF Aβ42+ tau levels.
|
31849573 |
2019 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
With a single molecule array method (Simoa, Quanterix), plasma NfL concentrations were measured in 99 subjects with AD at the stage of mild cognitive impairment (MCI-AD; n = 25) or at the stage of early dementia (ADD; n = 33), and in nondemented controls (n = 41); in all patients, the clinical diagnoses were in accordance with the results of the four core cerebrospinal fluid (CSF) biomarkers (amyloid β (Aβ)1-42, Aβ42/40, Tau, and pTau181), interpreted according to the Erlangen Score algorithm.
|
30055655 |
2018 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Determine the added diagnostic value of cerebrospinal fluid (CSF) biomarkers for differential dementia diagnosis as compared to autopsy-confirmed diagnosis.
|
29614653 |
2018 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Performance of the CSF biomarkers was optimal in the asymptomatic versus Alzheimer's disease dementia comparison (AUC ≥0·90 for all except Aβ<sub>1-40</sub> [0·59, 0·45-0·72]).
|
30172624 |
2018 |
|
Dementia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Correction: Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia.
|
30365556 |
2018 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this multicentre study in clinical settings, we assessed the accuracy of optimized procedures for FDG-PET brain metabolism and CSF classifications in predicting or excluding the conversion to Alzheimer's disease (AD) dementia and non-AD dementias.
|
29387532 |
2018 |